EKSO BIONICS HOLDINGS, INC.

EKSO

Explore Our Financial Data > Companies > EKSO BIONICS HOLDINGS, INC.
{{popupValue}}
{{popupSubtitle}}
Documentation
Excel
API
Download

Identification

Click on a field for details on how to access that data via Web API, Excel, or CSV Download.

Ticker
EKSO
CIK0001549084
SIC3569
SectorManufacturing
Industry CategoryMachinery
Industry GroupGeneral Industrial Machinery & Equipment

Contact

Address101 GLACIER POINT, SUITE A, SAN RAFAEL, CA, 94901
Website eksobionics.com
Phone510-984-1761
CEOSteven Sherman
Employees60

Access This Data

Our team will help you customize a package that meets the needs of your business.

Request a Consultation

Standardized Financials

docs

Intrinio provides professional-grade historical financial data. This data is standardized, cleansed and verified to ensure the highest quality data sourced directly from the XBRL financial statements. The primary purpose of standardized financials are to facilitate comparability across a single company’s fundamentals and across all companies fundamentals.

For example, it is possible to compare total revenues between two companies as of a certain point in time, or within a single company across multiple time periods. This is not possible using the as reported financial statements because of the inherent complexity of reporting standards.

Below is a preview of several data points from each financial statement, as well as a sample of our many calculated metrics:

Income Statement
Revenue$14.65 million
Pre-Tax Income$-11.08 million
Net Income$-11.08 million
Net Income to Common$-11.08 million
EPS$-5.08
View All
Balance Sheet
Cash$5.24 million
Assets$23.17 million
Liabilities$12.24 million
Common Equity$10.93 million
Liabilities & Equity$23.17 million
View All
Cash Flow Statement
Net Income$-11.08 million
Cash From Operating Activities$-9.12 million
Cash From Investing Activities$-79,000.00
Cash From Financing Activities$8.52 million
Change in Cash$-643,000.00
View All
Calculations
NOPAT$-8.60 million
EBITDA$-9.25 million
Price to EarningsN/A
Price to Book$0.73
ROE-96.44%
View All

Latest News

docs

Intrinio provides up-to-date news articles on every US company from various sources. Here are several examples:

Ekso Bionics Holdings Second Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag

Ekso Bionics Holdings ( NASDAQ:EKSO ) Second Quarter 2025 Results Key Financial Results Revenue: US$2.06m (down 58...

Article Link

Ekso Bionics Holdings Inc (EKSO) Q2 2025 Earnings Call Highlights: Navigating Revenue Decline ...

Despite a challenging quarter, Ekso Bionics Holdings Inc (EKSO) focuses on growth in personal health products and strategic partnerships to drive future success.

Article Link

Ekso Bionics (EKSO) Reports Q2 Loss, Misses Revenue Estimates

Ekso Bionics (EKSO) delivered earnings and revenue surprises of -3.33% and -55.57%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Article Link

Ekso Bionics: Q2 Earnings Snapshot

SAN RAFAEL, Calif. AP) — Ekso Bionics Holdings Inc. EKSO) on Monday reported a loss of $2.7 million in its second quarter.

Article Link

Ekso Bionics Reports Second Quarter 2025 Financial Results

SAN RAFAEL, Calif., July 28, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (“Ekso Bionics” or the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today reported financial results for the three and six months ended June 30, 2025. Recent Highlights and Accomplishments Named Bionic Prosthetics & Orthotics Group (“Bionic P&O”) as its first Ekso Indego Personal device distributor within the orthotics and prosthetics industryAccepted into

Article Link